Treatment of superficial bladder cancer with intravesical perfusion of rIL-2: A follow-up study

Anticancer Research

Volumn 16, Issue 2, 1996, Pages 979-980

  Ferlazzo, Guido ^a   Magno, Carlo ^b   Iemmo, Raffaella ^b   Rizzo, Massimo ^b   Lupo, Giuseppe ^b   Semino, Claudia ^c   Bruno, Silvia ^c   Meliol, Giovanni ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Bladder cancer; Intravesical perfusion; Recombinant interleukin 2

Indexed keywords

BCG VACCINE; CYTOKINE; RECOMBINANT INTERLEUKIN 2;

ARTICLE; BLADDER CANCER; BLADDER IRRIGATION; CLINICAL ARTICLE; CLINICAL TRIAL; CYSTOSCOPY; CYTOLOGY; DRUG EFFICACY; FOLLOW UP; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; TRANSURETHRAL RESECTION;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-2; NEOPLASM RECURRENCE, LOCAL; RECOMBINANT PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 0030010761     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Herr HW, Pinsky CM, Whitmore WF, Whitmore WF Jr, Oettgen HF and Melamed MR: Effect of intravesical bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder. Cancer 57: 1323-1326, 1983.
2. Lamm DL, Van Der Meijden L, Morales A et al: Incidence and treatment of complications of Bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 747: 596-600, 1992.
3. Orihuela E, Herr HW, Pinsky CM and Whitmore WF Jr: Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer 60: 326-333, 1987.
4. Ferlazzo G, Magno C, Lupo G et al: A phase I study of intravesical continuous perfusion of recombinant Interleukin-2 in patients with superficial bladder cancer. Am J Clin Oncol 18: 100-104, 1994.